We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Molecular Genetics Studies of Cancer Patients and Their Relatives

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04185935
Recruitment Status : Recruiting
First Posted : December 4, 2019
Last Update Posted : September 16, 2022
National Cancer Institute (NCI)
Information provided by (Responsible Party):
City of Hope Medical Center

Brief Summary:
This trial studies the genetic and behavioral factors that may contribute to the development of specific cancers and how these factors may affect the outcome of the disease in patients with a history of cancer and their relatives.

Condition or disease Intervention/treatment
Malignant Neoplasm Other: Biospecimen Collection Other: Questionnaire Administration

Detailed Description:


I. To identify rare cancer patients and families in whom the pattern of disease suggests a genetic susceptibility to cancer or other etiology suggestive of a carcinogenic exposure and to characterize the underlying predisposition.

II. To determine the contribution of heredity (genotype) and biomarkers to clinical outcome (phenotype, occurrence of new cancers, prognosis and quality of life) in subgroups of cancer patients with and without clinical high-risk features.


Patients may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 999999 participants
Observational Model: Family-Based
Time Perspective: Prospective
Official Title: Molecular Genetics Studies of Cancer Patients and Their Relatives
Actual Study Start Date : April 18, 1997
Estimated Primary Completion Date : May 5, 2030
Estimated Study Completion Date : May 5, 2030

Group/Cohort Intervention/treatment
Ancillary-correlative (biospecimen collection)
Participants may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.
Other: Biospecimen Collection
Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue

Other: Questionnaire Administration
Ancillary studies

Primary Outcome Measures :
  1. Cancer risk assessment [ Time Frame: Up to 10 years ]
  2. Exploratory biomarkers for future studies [ Time Frame: Up to 10 years ]

Biospecimen Retention:   Samples With DNA
Blood, saliva, eyebrow pluck, urine, tissue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Participants with a family history of cancer

Inclusion Criteria:

  • Individuals must have a personal history of cancer and/or a family history of cancer suggestive of the presence of an inherited predisposition. This inherited predisposition might manifest as:

    • Young age cancer diagnosis
    • Multiple primary neoplasms in affected member
    • The presence of rare tumor types in the family
    • Congenital malformations
    • Any other family clustering of cancer
    • Any other cancer-predisposing genetic diseases/conditions
  • Individuals may also be eligible by participation in the City of Hope Cancer Screening & Prevention Program Network (CSPPN) clinical service or on the basis of membership in a group known or suspected to have an increased risk of carrying a genetic alteration or of sustaining a particular exposure that would place that at increased risk of cancer. (Examples would include members of occupational cohorts like asbestos workers, individuals with multiple dysplastic nevi in the absence of a family history of cancer, and individuals descended from a particular tribe in the American Southwest who have an increased incidence of a rare genetic alteration associated with an increased risk of a specific cancer.)
  • Individuals and families may be referred to us in a number of different ways. After initial contact is made with a individual or family by family studies personnel; an individual within the bloodline will be identified as the historian. There may be more than one historian within a family
  • At least one historian must be wiling to provide information or access as needed to contact appropriate family members for documentation of cancer and for consent. An individual is considered to be eligible to participate if they criteria; contact with relatives is not always indicated
  • Individuals who are under 18 are eligible for study if they meet the criteria. Consent for participation must be given by a legal guardian or parent
  • Deceased patients may be included in the study. Public records, such as death certificates, can be used to confirm information from individuals or family members. If medical records are needed, consent for these records will be obtained from the deceased's next of kin. Next of kin refers to the following hierarchy of relatives; spouse, offspring, parents, and siblings. (Any further use of next of kin in this protocol should relate back to this hierarchy.) Archived tissue samples, such as pathology blocks or snap frozen tumor from a pathology department tumor bank (discard specimens) may be used for genetic research

Exclusion Criteria:

  • A family may be ineligible for study if the historian will not allow access to anyone within the family and thus, the accuracy of the family history cannot be established

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04185935

Show Show 42 study locations
Sponsors and Collaborators
City of Hope Medical Center
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Jeffrey N Weitzel City of Hope Medical Center
Layout table for additonal information
Responsible Party: City of Hope Medical Center
ClinicalTrials.gov Identifier: NCT04185935    
Other Study ID Numbers: 96144
NCI-2019-05695 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
96144 ( Other Identifier: City of Hope Comprehensive Cancer Center )
First Posted: December 4, 2019    Key Record Dates
Last Update Posted: September 16, 2022
Last Verified: September 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms